The etiologic role of Epstein-Barr virus and Cytomegalovirus infections in breast cancer development: a meta-analysis of case-control studies

Keywords
risk, Breast cancer, Epistein Barr Virus, Cytomegalovirus, Meta-analyses

Abstract

Introduction

The implication of viral infection in alterations of vital cellular pathways and genomic integration and thus, human carcinogenesis is well documented in molecular epidemiology studies. EBV and CMV are two of the most studied human viruses for potential association with cancer risk, progression, and outcome. The contradicting reports as for the etiologic role of these viruses in breast cancer entailed the conduction of the current meta-analysis

Material and methods

A thorough comprehensive electronic search was performed using PubMed, EMBASE, and Web of Science databases for relevant publications until February 28, 2021 based on predefined eligibility criteria. Extracted data from eligible studies were used to calculate the pooled effect size, heterogeneity, publication bias, sensitivity, and subgroup analyses for both viruses independently. Meta-analyses were performed using Prometa 3 software.

Results

For EBV, a total of 19 studies were included, while 8 studies were included for CMV. A significantly high risk of breast cancer with EBV infection (OR = 5.04, 95%CI: 3.44 – 7.39, P < 0.05), a similar, though smaller risk with CMV (OR = 4.53, 95%CI: 2.04 – 10.03, P < 0.05). EBV studies in which viral genetic material was detected in fresh breast cancer tissue showed higher risk compared to studies relied upon FFPE specimen. Conversely, for CMV, the FFPE studies showed a higher risk compared to studies relying upon fresh breast cancer tissues.

Conclusions

It can be inferred that infection with either of the two viruses increases the risk of breast cancer, suggesting an etiologic role of these viruses in breast carcinogenesis.

Abstract

Introduction

The implication of viral infection in alterations of vital cellular pathways and genomic integration and thus, human carcinogenesis is well documented in molecular epidemiology studies. EBV and CMV are two of the most studied human viruses for potential association with cancer risk, progression, and outcome. The aim of this study is to assess the association of EBV and CMV infections with the risk of breast cancer, in pursuit of an accurate estimate of effect of these potential risk factors.

Material and Methods

A thorough comprehensive electronic search was performed using the PubMed, EMBASE and Web of Science databases for relevant publications until February 28, 2021, based on predefined eligibility criteria. Data extracted from eligible studies were used to calculate pooled effect size, heterogeneity, publication bias, sensitivity, and subgroup analyses for both viruses independently. Meta-analyses were performed using Prometa 3 software.

Results

For EBV, a total of 19 studies were included, while 8 studies were included for CMV. A significantly high risk of breast cancer with EBV infection (OR = 5.04, 95% CI 3.44 – 7.39, $P < 0.05$), a similar, though smaller, risk with CMV (OR = 4.53, 95% CI 2.04 – 10.03, $P < 0.05$). EBV studies in which viral genetic material was detected in fresh breast cancer tissue showed higher risk compared to studies relied upon FFPE specimen. Conversely, for CMV, the FFPE studies showed a higher risk compared to studies relying upon fresh breast cancer tissues.

Conclusions

It can be inferred that infection with either of the two viruses increases the risk of breast cancer, suggesting an etiologic role of these viruses in breast carcinogenesis.

Introduction

Cancer is a leading cause of death globally and accounts for nearly 10 million deaths in 2020 [1]. Breast cancer (BC), the most common cancer among women, is significantly recognized as a heterogeneous disease characterized by unique pathological characteristics, including morphology, grade, and hormone receptor profile. In addition, hormone receptors are used to divide tumors into clinically and biologically differentiated groups based on their characteristics [2]. There were an estimated 2.26 million newly diagnosed cases of breast cancers in 2020 [3]. Furthermore, breast cancer is diagnosed in the United States at an annual rate of more than 200,000 cases [4]. As defined in epidemiological studies, age, heredity, diet, tobacco use, and inflammation have all been identified as risk factors for cancer [5]. Interestingly, evolving body of study estimated that approximately 20% of human cancers could be interrelated to virus infection encompassing Epstein–Barr virus (EBV) in addition to cytomegaloviruses (CMV) [6-10]. Several types of human cancer have been reported to contain the CMV genome and antigens, including breast cancer, brain cancer, prostate cancer, colon cancer [11-14]. Furthermore, millions of people are being infected with viruses around the world. Many of them are still at increased risk for cancer due to viral infection [15]. On the other hand, the idea that virus infections cause cancer has been neglected for many years.

In recent years, there has been increasing evidence that has helped us understand the association between viral infections and cancer, including breast cancer [15-17]. In the present meta-analysis, we have attempted to explore EBV and CMV's role in breast cancer potentially leading to new insight into how this disease incites, advances and can be detected, diagnosed and treated early.

Materials and methods

Literature search strategy

The present meta-analysis was carried out following the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) and the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We searched for relevant literature published until February 28, 2021 in the PubMed, EMBASE, and Web of Science databases, using the combination of the following search terms: “Epstein-Barr/EBV” or "Cysteomegalovirus/Virus”, with “Breast/Mammary”, “Cancer/Carcinoma/Tumor”, “Risk/Association”. Open Grey, MedRxiv, BioRxiv, and Open Science Framework (OSF) preprints were searched for grey literature. Additionally, references lists of all potentially eligible articles were manually searched.

Eligibility criteria and quality assessment

Eligible studies included in this meta-analysis met the following inclusion criteria: (1) case control design carried out on patients with breast cancer alone, (2) viral DNA examined in breast tissues in both study arms, (3) detection of viral genetic material is performed by real-time PCR or PCR, (4) clear pathological diagnosis, (5) studies reported odds ratio and the corresponding 95% confidence interval or enough data to calculate these values, the corresponding authors were contacted in case of missing data, (6) published in English language.

Studies were excluded if conducted on specimens from non-human sources, reviews, editorials, case studies, viral DNA was not detected in both study arms.

We assessed the quality of each study using the modified Newcastle-Ottawa Scale (NOS) for case control studies [18]. To calculate a total quality score, we assessed criteria that cover selection, comparability, and exposure. A study can be awarded a maximum of one point for each item within the selection and exposure categories and a maximum of two points for comparability, with a total of 9 attainable points. Studies with a score ≥ 7 are considered of high quality, 5 – 7 moderate quality and < 5 poor quality.

The quality rating for each item was carried out independently by two reviewers and disagreements were resolved by consensus.

Data extraction

Data from eligible studies were extracted by one reviewer (BK) and verified by the second reviewer (KM) using data extraction table, the data included the name of the author, year of publication, the population studied, type of specimen, viral gene or primers used, type of breast cancer, method for detection of viral DNA, total number of cases and controls, number of positive cases and controls, odds ratio, and 95% confidence interval.

Statistical analysis

The present meta-analysis was performed using Prometa3 software. We computed the pooled estimate (OR) and 95% confidence interval by means of random effects model (DerSimonian Laird method). The heterogeneity among studies was estimated using Cochran Q statistic and I^2. Heterogeneity was considered insignificant with $I^2 < 40\%$, moderate heterogeneity with I^2 between 40% and 60%, and substantial heterogeneity with $I^2 > 60\%$.

Publication bias was evaluated with the funnel plot, Egger's linear regression test, and the Begg and Mazumdar rank correlation test, with a *P*. value < 0.1 indicates potential bias. Sensitivity analysis was also performed to assess the influence of each individual study.

Results

Identification and retrieval of studies

A total of 14,260 articles were retrieved through a systematic search of the three databases for EBV and breast cancer. Additionally, 67 articles were identified through grey literature and manual search (Fig.1). Following the removal of duplicates and irrelevant articles, 482 articles were subjected to title and abstract screening, resulting in the exclusion of 246 articles. For the remaining 236 articles, a full text evaluation was carried out that led to further exclusion of 217 articles, out of which 139 articles due to lack of extractable data, 52 articles of different

study design, and 26 studies that relied on techniques other than PCR or qPCR for viral DNA identification 26 articles. Ultimately, 19 articles were included in this meta-analysis.

On the other hand, the search for records on CMV resulted in 13522 articles from database search, in addition to 37 articles identified through grey literature and manual search. The removal of duplicates and irrelevant articles led to 235 articles, which were then screened based on title and abstract, a process that lead to further exclusion of 181 articles, the full text of the remaining 54 articles was thoroughly assessed for eligibility, which led to 8 studies included in the final meta-analysis (Fig. 2).

Study Characteristics

The 19 EBV studies included in the present meta-analysis covered relatively large geodemographic variations, with a sample size of 2815 participants, encompassing 3 studies each from Australia, and Iran, 2 studies each from France, England, and Egypt, and one study each from New Zealand, Argentina, Tunisia, Jordan, Sudan, Eretria and Pakistan. The viral genes investigated in these studies included EBER genes, EBNA-1, BamH1W, BALF5, BamHIC, BamHiG, EBER-2, and LMP-1.

On the other hand, the eight CMV studies consisted of two studies each from Egypt and Iran and one study each from the United States, Mexico, New Zealand and Taiwan. While the viral genes investigated by these studies included IE1, IE2, GB region, and PP65 from either paraffin-embedded or fresh breast tissues (Table 1). Upon quality assessment, all studies showed a quality score of ≥7 on the NOS tool, indicating high quality (Fig. 3).

Meta-analysis and heterogeneity

The pooled effect size for the association of EBV and cytomegalovirus infections and the risk of breast cancer was estimated using the DerSimonian Laird method of the random effects model (OR= 5.04, 95% CI: 3.44 – 7.39) for EBV and (OR= 4.53, 95% CI: 2.04 – 10.03) for CMV. The random effects model was used in meta-

analyses for both viruses despite the relatively low heterogeneity between the EBV studies (Q = 20.44, *P* value = 0.308, I^2 = 11.95%) and moderate heterogeneity between the CMV studies (Q = 14.85, *P* value 0.038, I^2 = 52.85%) (Fig. 4, 5).

Sensitivity analysis and publication bias

Sensitivity analysis was carried out by repeating the primary meta-analysis accompanied by removal of one study at a time during the analysis and detect for any effect size alteration due to presence of any arbitrary values in these studies. The lack of significant change in the pooled effect size for studies of both viruses indicated the stability of the present meta-analyses. Furthermore, publication bias was assessed using the Begg and Mazumdar rank correlation test, Egger's linear regression test, and funnel plot. Neither Begg's test (EBV: *Z* = 0.31, *P*. value = 0.753) (CMV: Z = 0.25, *P* value = 0.805), Egger's test (EBV: t = 2.12, *P* value = 0.05) (CMV: t = -0.34, *P* value = 0.746), the funnel plots (Fig. 6, 7) showed no evidence of any publication bias.

Subgroup analysis

Subgroup analysis was carried out to determine the difference in the risk of breast cancer with viral infection according to the type of sample used for viral detection and to highlight the source of heterogeneity among the included studies. For EBV, slight difference was noted in the risk of breast cancer when fresh or frozen breast tissues were used (OR= 5.51, 95%CI: 3.42 – 8.89, *P*. value = 0.000) with extremely low heterogeneity (Q = 8.05, *P*. value = 0.429, I^2 = 0.57%) compared to formalin-fixed paraffin-embedded specimen (FFPE) (OR= 4.51, 95%CI: 2.48 – 8.20, *P*. value = 0.000) with slightly raised heterogeneity (Q = 11.88, *P*. value = 0.220, I^2 = 24.22%) (Fig. 8). While for CMV, the fresh/frozen breast tissues showed slightly lower risk of association, although statistically not significant (OR= 3.65, 95%CI: 0.94 – 14.14, *P*. value = 0.061) and significant heterogeneity (Q = 12.35, *P*. value = 0.006, I^2 = 75.71%) as compared to higher risk in FFPE subgroup (OR= 4.12, 95%CI: 1.81 – 9.38, *P*. value = 0.001) with no heterogeneity (Q = 2.35, *P*. value = 0.504, I^2 = 0.00%) (Fig. 9)

Discussion

Cancer is the second leading cause of death worldwide, preceded only by cardiovascular diseases, and breast cancer ranks second among the most commonly occurring cancers overall [19].

Beside its ability to easily infect B lymphocytes, EBV can also infect epithelial cells, but not with the same ease. The virus uses different sets of envelop proteins to bind and enter these cells, namely, gp350 protein for the former and gp40 protein for the later [20]. The virus is known to promote oncogenesis with the help several intriguing products that interfere with apoptosis, cause genomic instabilities, cellular transformation and metastasis [21].

Similarly, CMV is characterized by its life-long latency following the evasion of the immune system responses. Upon its reactivation, it expresses several proteins such as US27, US28 and UL78, that increase the host cell metabolism, enable the cell to avoid G1 phase and ultimately transforming the host cell [12, 22].

In the present meta-analysis, we attempted to unravel the etiological role of EBV and CMV in breast carcinogenesis, raising the prospect of an exploitable relation for better understanding disease induction, progression, and early detection, diagnosis, treatment, and possible prophylaxis. We examined the association of EBV infection on one hand and CMV infection on the other hand with the risk of breast cancer. Ten of the 19 studies included in the meta-analysis of EBV showed a significantly higher risk of breast cancer with EBV infection, while 4 out of 8 studies in CMV showed a significantly higher risk of breast cancer with viral infection. Our findings showed that EBV infection increases the risk of developing breast cancer five times, and four and a half times with CMV infection.

The etiological roles of EBV and CMV in the risk of breast cancer were previously explored under different contexts, however, contradicting results were reported, with several studies [18, 19, 23-25] reporting a lack of possible association between EBV and breast cancer, while other studies [26-28] suggest strong association. Similar contradictory results were also reported for CMV [29-31]

Our results are consistent with the findings reported in previous studies [28, 32, 33], although EBV infection in these studies was detected differently using *in situ* hybridization (ISH) and immunohistochemistry (IHC) techniques, the level of risk of breast cancer remained consistent with our pooled effect size. Similar consistency was also observed with previous studies [32] in the results of CMV infection.

EBV infection was involved in several epithelial and lymphatic neoplasms, including gastric cancer [34] , hepatobiliary system cancer [35] , nasopharyngeal carcinoma [36] Hodgkin's lymphoma [37], and non-Hodgkin lymphomas [38]. The virus is believed to promote tumorigenesis through different pathways, such as the expression of the viral protein LMP1, which activates the Her2/Her3 signaling cascades in mammary cells [39].

The oncogenic properties of CMV, such as the expression of four genes that encode G-protein-coupled receptor (GPCR)-like proteins, namely US27, US28, UL33 and UL78, which play a key role in the signaling pathways of cAMP and PI3K, are important for anchorage-independent cell growth and epithelial cell transformation [40, 41]. These genes qualified the virus to play an important role in many cancers and other diseases [12, 42-44].

We carried out a subgroup analysis based on the type of sample used for the detection of viral DNA, FFPE, or fresh / frozen tissues, to determine the source of heterogeneity and detect variations in the risk of breast cancer according to the sample used.

A relatively low heterogeneity was detected between the studies used for the quantitative synthesis of the relationship between EBV and breast cancer risk. The subgroup analysis revealed that the major contributors to this heterogeneity were studies involving the use of FFPE specimen. This study also showed a higher risk of breast cancer when fresh breast tissues are used (OR= 5.5, 95%CI: 3.42 – 8.89, P = 0.000) compared to studies based on the FFPE cancer specimen (OR= 4.51, 95%CI: 2.48 – 8.20, P = 0.000), which agrees with the findings reported by Farahmand *et al*. [45], this indicates that fresh breast tissues are the best specimen

to detect EBV. Conversely, studies included in CMV meta-analysis showed a much higher heterogeneity, and most of which was contributed by studies involved the use of fresh breast tissues specimen, while there was no heterogeneity between studies involved the use of FFPE specimen. This variation in heterogeneity apparently impacted the level of breast cancer risk in the two subgroups, with the subgroup involving the use of fresh breast tissue showing a lower risk of breast cancer, although statistically not significant (OR= 3.65, 95% CI 0.94 – 14.14, *P* = 0.061) as compared to the higher risk in the FFPE subgroup (OR= 4.12, 95% CI 1.81 – 9.38, *P* = 0.001).

Conclusion

In conclusion, infection with either of the two viruses significantly increases the risk of breast cancer, this risk is slightly higher with EBV infection compared to CMV infection nonetheless, suggesting an etiological role of these two viruses in breast carcinogenesis and potential value in early detection, treatment, and prevention of the disease. The current meta-analysis explored the association of each of the two viruses with the risk of breast cancer independently; further comprehensive studies are recommended exploring the combined risk of the two viruses.

Authors' Contributions

B.K. and K.A. contributed equally to the study design, extraction of data, data quality assessment, statistical analysis, and writing of the manuscript. B.K. performed the initial searches and K.A. performed the final analysis. A. M assist with search methods, extract data, and review the manuscript. M. A assisted with statistical analyses and reviewed the manuscript; MU. A provided input into the extraction of the data and reviewed the manuscript; M.E provided input into the analysis and reviewed the manuscript; B. K supervised the study design, analysis and interpretation, and reviewed and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors would like to acknowledge the support provided by the Deanship of Scientific Research at University of Bisha, Saudi Arabia, for funding this work (grant number UB-50-1438).

Statement of Ethics

The authors have no ethical conflicts to disclose.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Data Availability

All data supporting our findings were incorporated within the article. Raw data can be presented by the principal investigator upon request

References

1. Ferlay, J., et al., *Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon*. 2020.
2. Clark, M., *Prognostic and predictive factors.* Breast Disease, 1996: p. 461-480.
3. Sung, H., et al., *Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.* CA: a cancer journal for clinicians, 2021. **71**(3): p. 209-249.
4. DeSantis, C.E., et al., *Breast cancer statistics, 2019.* CA: a cancer journal for clinicians, 2019. **69**(6): p. 438-451.
5. Anand, P., et al., *Cancer is a preventable disease that requires major lifestyle changes.* Pharmaceutical research, 2008. **25**(9): p. 2097-2116.
6. Hausen, H.z., *Viruses in human cancers.* Current Science, 2001: p. 523-527.
7. Parkin, D.M., *The global health burden of infection-associated cancers in the year 2002.* International journal of cancer, 2006. **118**(12): p. 3030-3044.
8. Taher, C., et al., *High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes.* PloS one, 2013. **8**(2): p. e56795.
9. Joshi, D., et al., *Association of Epstein Barr virus infection (EBV) with breast cancer in rural Indian women.* PloS one, 2009. **4**(12): p. e8180.
10. Ghaffari, H., et al., *Human cytomegalovirus and Epstein-Barr virus infections in breast cancer: A molecular study on Iranian women.* Breast Disease, 2021(Preprint): p. 1-7.
11. Richardson, A., et al., *Breast cancer and cytomegalovirus.* Clinical and Translational Oncology, 2020. **22**(4): p. 585-602.
12. Geisler, J., et al., *A review of the potential role of human cytomegalovirus (HCMV) infections in breast cancer carcinogenesis and abnormal immunity.* Cancers, 2019. **11**(12): p. 1842.
13. Limam, S., et al., *Investigation of Human Cytomegalovirus and Human Papillomavirus in Glioma.* Cancer Investigation, 2020. **38**(7): p. 394-405.
14. Luo, X.H., et al., *The impact of inflationary cytomegalovirus-specific memory T cells on anti-tumour immune responses in patients with cancer.* Immunology, 2018. **155**(3): p. 294-308.
15. De Martel, C. and S. Franceschi, *Infections and cancer: established associations and new hypotheses.* Critical reviews in oncology/hematology, 2009. **70**(3): p. 183-194.
16. Sarid, R. and S.-J. Gao, *Viruses and human cancer: from detection to causality.* Cancer letters, 2011. **305**(2): p. 218-227.
17. Mofrad, M.G., et al., *Detection of human papillomavirus genotypes, herpes simplex, varicella zoster and cytomegalovirus in breast cancer patients.* Virology Journal, 2021. **18**(1): p. 1-10.
18. Dowran, R., et al., *No detection of EBV, BKV and JCV in breast cancer tissue samples in Iran.* BMC research notes, 2019. **12**(1): p. 1-5.
19. Kadivar, M., et al., *Epstein-Barr virus and breast cancer: lack of evidence for an association in Iranian women.* Pathology & Oncology Research, 2011. **17**(3): p. 489-492.
20. Tsang, C.M. and S.W. Tsao, *The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.* Virologica Sinica, 2015. **30**(2): p. 107-121.
21. Fernandes, Q., et al., *Role of Epstein–Barr virus in the pathogenesis of head and neck cancers and its potential as an immunotherapeutic target.* Frontiers in oncology, 2018. **8**: p. 257.

22. Kumari, P., et al., *Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways.* Cell death & disease, 2017. **8**(10): p. e3078-e3078.
23. Perrigoue, J.G., et al., *Lack of association between EBV and breast carcinoma.* Cancer Epidemiology and Prevention Biomarkers, 2005. **14**(4): p. 809-814.
24. Preciado, M.V., *Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma–another point of view.* Breast Cancer Research, 2003. **5**(4): p. 1-1.
25. Fimereli, D., et al., *No significant viral transcription detected in whole breast cancer transcriptomes.* BMC cancer, 2015. **15**(1): p. 1-9.
26. Ayee, R., et al., *Epstein Barr virus associated lymphomas and epithelia cancers in humans.* Journal of Cancer, 2020. **11**(7): p. 1737.
27. Nagi, K., et al., *High-risk human papillomaviruses and Epstein–Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study.* Cancer Cell International, 2021. **21**(1): p. 1-10.
28. El-Naby, N.E.H., et al., *Epstein-Barr virus infection and breast invasive ductal carcinoma in Egyptian women: a single center experience.* Journal of the Egyptian National Cancer Institute, 2017. **29**(2): p. 77-82.
29. Utrera-Barillas, D., et al., *Is human cytomegalovirus associated with breast cancer progression?* Infectious agents and cancer, 2013. **8**(1): p. 1-5.
30. Costa, H., et al., *Human cytomegalovirus infection is correlated with enhanced cyclooxygenase-2 and 5-lipoxygenase protein expression in breast cancer.* Journal of cancer research and clinical oncology, 2019. **145**(8): p. 2083-2095.
31. Branch, K.M., et al., *Productive Infection of Human Breast Cancer Cell Lines with Human Cytomegalovirus (HCMV).* Pathogens, 2021. **10**(6): p. 641.
32. Pai, T., et al., *Evidence for the association of Epstein-Barr Virus in breast cancer in Indian patients using in-situ hybridization technique.* The breast journal, 2018. **24**(1): p. 16-22.
33. Su, J., D. Yan, and S. Wu, *Epstein-Barr virus infection and increased sporadic breast carcinoma risk: a meta-analysis.* Medical Principles and Practice, 2020. **29**(2): p. 195-200.
34. Nishikawa, J., et al., *Clinical importance of Epstein–Barr virus-associated gastric cancer.* Cancers, 2018. **10**(6): p. 167.
35. Chen, Z.-x., et al., *EBV as a potential risk factor for hepatobiliary system cancer: A meta-analysis with 918 cases.* Pathology-Research and Practice, 2019. **215**(2): p. 278-285.
36. Hau, P.M., et al., *Targeting Epstein-Barr virus in nasopharyngeal carcinoma.* Frontiers in Oncology, 2020. **10**: p. 600.
37. Massini, G., D. Siemer, and S. Hohaus, *EBV in Hodgkin lymphoma.* Mediterranean journal of hematology and infectious diseases, 2009. **1**(2).
38. Shannon-Lowe, C., A.B. Rickinson, and A.I. Bell, *Epstein–Barr virus-associated lymphomas.* Philosophical Transactions of the Royal Society B: Biological Sciences, 2017. **372**(1732): p. 20160271.
39. Hu, H., et al., *Epstein–Barr virus infection of mammary epithelial cells promotes malignant transformation.* EBioMedicine, 2016. **9**: p. 148-160.
40. Moussawi, F.A., et al., *The transcriptome of human mammary epithelial cells infected with the HCMV-DB strain displays oncogenic traits.* Scientific reports, 2018. **8**(1): p. 12574-12574.
41. Boroughs, L.K. and R.J. DeBerardinis, *Metabolic pathways promoting cancer cell survival and growth.* Nature cell biology, 2015. **17**(4): p. 351-359.
42. Yin, M., et al., *Detection of human cytomegalovirus in patients with epithelial ovarian cancer and its impacts on survival.* Infectious agents and cancer, 2020. **15**(1): p. 1-8.

43. Halenius, A. and H. Hengel, *Human cytomegalovirus and autoimmune disease.* BioMed research international, 2014. **2014**.
44. Hu, J., et al., *Human cytomegalovirus and Epstein-Barr virus infections, risk factors, and their influence on the liver function of patients with acute-on-chronic liver failure.* BMC infectious diseases, 2018. **18**(1): p. 1-8.
45. Farahmand, M., et al., *Epstein–Barr virus and risk of breast cancer: a systematic review and meta-analysis.* Future Oncology, 2019. **15**(24): p. 2873-2885.

Table.1 Characteristics of studies included in the EBV and CMV meta-analyses

EBV							
Author	**year**	**Country**	**Specimen type**	**Primer/ gene**	**Type of BC**	**Detection method**	**Quality score**
Abdel-Rahman	2012	Egypt	FFPE	EBNA-1	IDC	qPCR	8
Ann	2015	New Zealand	Fresh BC tissues	EBNA-1	IDC	qPCR	9
Annika	2012	Australia	Frozen tissues	BALF5	IDC	qPCR	8
Chia	2018	Iran	FFPE	EBNA 3C	DC	qPCR	8
Fina	2001	France	Fresh BC tissues	BamHIC	IDC	qPCR	8
Ghimja	2017	Eretria	FFPE	EBER	DC/LC	qPCR	7
James	2017	Australia	FFPE	EBNA-1	IDC/ILC	qPCR	9
Louise	1995	England	Fresh BC tissues	BamH1W	IDC/ILC	PCR	9
Mario	2010	Argentine	Fresh BC tissues	EBNA-1	IDC/ILC	qPCR	8
Maryam	2017	Iran	FFPE	BamH1W	MC/TC	qPCR	7
Mathilde	1999	France	Fresh BC tissues	EBER-2	DC/LC	PCR	7
Mohamed	2011	Tunisia	Frozen tissues	BamHIG	DC /LC	PCR	9
Mohamed	2012	Jordan	FFPE	EBER-2	IDC/LC	qPCR	8
Morvarid	2020	Iran	FFPE	EBNA-1	IDC/ILC	qPCR	9
SA	2003	England	Fresh BC tissues	EBNA-1	DC/LC	PCR	8
Shereen	2008	Egypt	FFPE	EBNA-1	IDC/ILC	PCR	7
Wasifa	2017	Pakistan	FFPE	EBNA-2	DC/IDC	qPCR	9
Wendy	2012	Australia	FFPE	EBNA-1	DC in situ	qPCR	9
Zeinab	2014	Sudan	Fresh BC tissues	LMP-1	IL/IDC	qPCR	7
Cytomegalovirus							
Eghbali	2012	Iran	FFPE	GB	DC	PCR	9
El-shazly	2017	Egypt	Fresh BC tissues	IE2	IDC/ILC	qPCR	9
El-shinawi	2013	Egypt	Fresh BC tissues	IE2	IBC	PCR	8
Harkins	2010	USA	FFPE	IE1	BC	qPCR	8
Richardson	2015	New Zealand	Fresh BC tissue	PP65	IBC	qPCR	8
Sepahvand	2019	Iran	FFPE	GB	DC	PCR	7
Tasi	2005	Taiwan	Frozen tissues	IE2	IDC	PCR	9
Utrera-Barillas	2013	Mexico	FFPE	IE2	BC	qPCR	8

** FFPE: Formalin-fixed paraffin embedded, BC: breast cancer, IDC: Invasive ductal carcinoma, ILC: Invasive lobular carcinoma, MC: Modular carcinoma, DC: Ductal carcinoma, IBC: Invasive breast cancer, LC: lobular carcinoma



Fig. 1. PRISMA flowchart of studies included in EBV meta-analysis



Fig. 2. PRISMA flowchart of studies included in CMV meta-analysis



Fig. 3: Quality assessment of included studies using NOS tool (A) EBV, (B) Cytomegalovirus



Fig. 4. Forest plot of the association of EBV with the risk of breast cancer



Fig. 5. Forest plot of the association of CMV the risk of breast cancer



Fig. 6. Funnel plot for estimation of publication bias of EBV included studies



Fig. 7. Funnel plot for estimation of publication bias of CMV included studies



Fig. 8. Subgroup analysis for EBV and breast cancer according to the type of specimen



Fig. 9 Subgroup analysis of CMV and breast cancer according to the type of specimen